Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Ataxia

Treatments: Drug: Fondaparinux Sodium

Study type: Observational

Funder types: Industry

Identifiers

NCT01428531

115489

Details and patient eligibility

About

The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE).

("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)

Enrollment: 200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with acute pulmonary thromboembolism or acute deep venous thrombosis
• Fondaparinux injection must be prescribed for the first time

Exclusion criteria

• Not applicable

Trial design

200 participants in 1 patient group

Patients prescribed fondaparinux

Treatment:

Drug: Fondaparinux Sodium